تقنيات إعادة التأهيل الأرطفوني لاضطرابات الصوت والكلام لدى المصاب بمرض الباركنسون

Main Article Content

علي قدور

الملخص

حَتَّى الآنَ، لا تَوْجَدُ دِراسَةٌ مُوَثَّقَةٌ وَصَحِيحَةٌ عِلْمِيًّا تَقْدِمُ دَلِيلًا عَلَى فَعَّالِيَةِ عَمَلِيَّةِ إِعَادَةِ التَّأْهِيلِ الأَرْطُوفُونِيِّ لِاضْطِرَابَاتِ الصَّوْتِ وَالكَلامِ لَدَى المُصَابِينَ بِمَرَضِ البَارْكِنْسُون، وَذَلِكَ بِسَبَبِ أَحْجَامِ العَيِّنَاتِ الصَّغِيرَةِ جِدًّا. وَمَعَ ذَلِكَ، بَدْءًا مِنَ الثَّمَانِيَاتِ، فَإنَّ التَّدَابِيرَ المَوْضُوعِيَّةَ (التَّسْجِيلَاتِ المَرْأِيَّةِ، التَّحْلِيلُ الأَكُوسْتِيْكِي) وَنَتَائِجَ مَقَايِيسِ التَّقْيِيمِ الذَّاتِيِّ خَلَصَتْ إِلَى الفَعَّالِيَةِ الفَوْرِيَّةِ وَالمُتَوَسِّطَةِ المِدَى (3 إِلَى 12 شَهْرًا) لِإِعَادَةِ التَّأْهِيلِ الأَرْطُوفُونِيِّ لِهَذِهِ الِاضْطِرَابَاتِ، حَيْثُ أَضْحَى مِنَ المُمْكِنِ تَحْدِيدُ مَبَادِئِ إِعَادَةِ التَّأْهِيلِ النَّاجِعَةِ.


لِسُوءِ الحَظِّ فِي الجَزَائِرِ، هُنَاكَ أَقَلِّيَةٌ مِنَ المُخْتَصِّينَ الأَرْطُوفُونِيِّينَ الَّذِينَ يَتَكَلَّفُونَ بِاضْطِرَابَاتِ الصَّوْتِ وَالكَلامِ لَدَى المُصَابِينَ بِمَرَضِ البَارْكِنْسُون. مِنْ خِلَالِ بَحْثٍ بَبْلِيُوغْرَافِيٍّ عَلَى مَوْقِعِ وَزَارَةِ الصِّحَّةِ بِالْوِلَايَاتِ المُتَّحِدَةِ الأَمْرِيكِيَّةِ تَمَكَّنَا مِنَ التَّعَرُّفِ عَلَى الطُّرُقِ الرَّئِيسِيَّةِ الَّتِي يَعْتَمِدُهَا المُخْتَصُّونَ الأَرْطُوفُونِيُّونَ حَالِيًّا لِإِعَادَةِ تَأْهِيلِ اضْطِرَابَاتِ الصَّوْتِ وَالكَلامِ لَدَى مَرْضَى بَارْكِنْسُونَ الَّتِي سَنُعَرِّضُهَا بِالتَّفْصِيلِ فِي هَذِهِ الدِّرَاسَةِ.

Article Details

كيفية الاقتباس
قدور ع. (2025). تقنيات إعادة التأهيل الأرطفوني لاضطرابات الصوت والكلام لدى المصاب بمرض الباركنسون. دراسات إنسانية واجتماعية, 14(2), 919 - 926. https://doi.org/10.46315/1714-014-002-061
القسم
Articles

المراجع

1. Ascherio, A., & Schwarzschild, M. A.(2016). The epidemiology of Parkinson's disease: risk factors and prevention. The Lancet. Neurology*, 15(12), 1257–1272. https://doi.org/10.1016/S1474-4422(16)30230-7.
2. Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and Treatment of Parkinson Disease: A Review. JAMA, 323(6), 548–560. https://doi.org/10.1001/jama.2019.22360.
3. Beitz, J. M. (2014). Parkinson's disease: a review. Frontiers in bioscience (Scholar edition), 6(1), 65–74. https://doi.org/10.2741/s415.
4. Darley, F. L., Aronson, A. E., & Brown, J. R. (1969). Differential diagnostic patterns of dysarthria. Journal of speech and hearing research*, 12(2), 246–269. https://doi.org/10.1044/jshr.1202.246.
5. Dashtipour, K., Tafreshi, A., Lee, J., & Crawley, B. (2018). Speech disorders in Parkinson's disease: pathophysiology, medical management and surgical approaches. Neurodegenerative disease management, 8(5), 337–348. https://doi.org/10.2217/nmt-2018-0021.
6. Deane, K. H., Whurr, R., Playford, E. D., Ben-Shlomo, Y., & Clarke, C. E. (2001). Speech and language therapy for dysarthria in Parkinson's disease. The Cochrane database of systematic reviews, (2), CD002812. https://doi.org/10.1002/14651858.CD002812.
7. Fox, C., Ebersbach, G., Ramig, L., & Sapir, S. (2012). LSVT LOUD and LSVT BIG: Behavioral Treatment Programs for Speech and Body Movement in Parkinson Disease. Parkinsons Dis. , 2012, 391946. https://doi:10.1155/2012/391946.
8. Goldman, J. G., Volpe, D., Ellis, T. D., Hirsch, M. A., Johnson, J., Wood, J., Aragon, A., Biundo, R., Di Rocco, A., Kasman, G. S., Iansek, R., Miyasaki, J., McConvey, V. M., Munneke, M., Pinto, S., St Clair, K. A., Toledo, S., York, M. K., Todaro, R., Yarab, N., & Wallock, K. (2024). Delivering Multidisciplinary Rehabilitation Care in Parkinson's Disease: An International Consensus Statement. Journal of Parkinson's disease, 14(1), 135–166. https://doi.org/10.3233/JPD-230117.
9. Kaddour, A. (2018). La prise en charge de la dysarthrie par la méthode LSVT®. Grin Verlag Munich, ISBN : 9783668646414.
10. Le Huche, F., & Allali, A. (1989). La voix- Tome 4 : thérapeutique des troubles vocaux. Phoniatrie (3ème édition, Vol. Tome 4). Issy Les Moulineaux: Elsevier Masson.
11. Machado Sotomayor, M. J., Arufe-Giráldez, V., Ruíz-Rico, G., & Navarro-Patón, R. (2021). Music Therapy and Parkinson's Disease: A Systematic Review from 2015-2020. *International journal of environmental research and public health, 18(21), 11618. https://doi.org/10.3390/ijerph182111618.
12. Ma, A., Lau, K. K., & Thyagarajan, D. (2020). Voice changes in Parkinson's disease: What are they telling us?. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia, 72, 1–7. https://doi.org/10.1016/j.jocn.2019.12.029.
13. Pinto, S., Cardoso, R., Atkinson-Clement, C., Guimarães, I., Sadat, J., Santos, H., Mercier, C., Carvalho, J., Cuartero, M. C., Oliveira, P., Welby, P., Frota, S., Cavazzini, E., Vigário, M., Letanneux, A., Cruz, M., Brulefert, C., Desmoulins, M., Martins, I. P., Rothe-Neves, R., & Ferreira, J. J. (2024). Do Acoustic Characteristics of Dysarthria in People With Parkinson's Disease Differ Across Languages?. Journal of speech, language, and hearing research: JSLHR, 67(9), 2822–2841. https://doi.org/10.1044/2024_JSLHR-23-00525.
14. Ramig, L., Halpern, A., Spielman, J., Fox, C., & Freeman, K. (2018). Speech treatment in Parkinson's disease: Randomized controlled trial (RCT). Movement disorders: official journal of the Movement Disorder Society, 33(11), 1777–1791. https://doi.org/10.1002/mds.27460.
15. Radhakrishnan, N. N.(2022). Nasal Resistance (NR) Technique: A Novel Approach to Improve Glottal Adduction. J Voice, 36(1), 91-97. https://doi:10.1016/j.jvoice.2020.04.020.
16. Selikhova, M., Tripoliti, E., Fedoryshyn, L., Matvienko, Y., Stanetska, H., Boychuk, M., Komnatska, I., Lees, A. J., & Sanotsky, Y. (2016). Analysis of a distinct speech disorder seen in chronic manganese toxicity following Ephedrone abuse. Clinical neurology and neurosurgery, 147, 71–77. https://doi.org/10.1016/j.clineuro.2016.05.027.
17. Simon, D. K., Tanner, C. M., & Brundin, P. (2020). Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clinics in geriatric medicine, 36(1), 1–12. https://doi.org/10.1016/j.cger.2019.08.002.
18. Spielman, J., Mahler, L., Halpern, A., Gilley, P., Klepitskaya, O., & Ramig, L. (2011). Intensive voice treatment (LSVT®LOUD) for Parkinson’s disease following deep brain stimulation of the subthalamic nucleus. Journal of Communication Disorders, 44(6), 688–700.
19. Theodoros, D., & Anderson, A. (2024). Speech therapy for people with Parkinson's disease. BMJ (Clinical research ed.), 386, q1254. https://doi.org/10.1136/bmj.q1254.
20. Pinto, S., Ozsancak, C., Tripoliti, E., Thobois, S., Limousin-Dowsey, P., & Auzou, P. (2004). Treatments for dysarthria in Parkinson's disease. The Lancet. Neurology, 3(9), 547–556. https://doi.org/10.1016/S1474-4422(04)00854-3.